Costs of Peripheral Blood Progenitor Cell Transplantation Using Whole Blood Mobilised by Filgrastim as Compared With Autologous Bone Marrow Transplantation in Non-Hodgkin's Lymphoma
Carin A. Uyl-de Groot
Gert J. Ossenkoppele
Peter C. Huijgens
Objective: The aim of this paper is to compare the costs of autologous bone marrow transplantation (ABMT) and whole blood transplantation in patients with relapsed or poorly responding non-Hodgkin's lymphoma. Design and setting: In a retrospective study, we calculated the treatment costs of 40 patients who received either ABMT or, alternatively, whole blood mobilised by filgrastim (a granulocyte colony-stimulating factor. Main outcome measures and results: The recovery of granulocytes was markedly accelerated in the whole blood group as compared with the ABMT group. This resulted in a reduction in hospital costs, and costs for diagnostics and medical procedures, antibacterials, nutrition and blood transfusions. The average costs per patient in the whole blood group amounted to approximately $US16 890 as compared with approximately $US20 713 in the ABMT group (1995 values), implying a cost reduction of 18% when changing to whole blood reinfusion. Conclusions: With the premise that both therapies are equivalent, it seems that whole blood transplantation is more cost effective than ABMT.
In order to set up a list of libraries that you have access to,
you must first login
or sign up.
Then set up a personal list of libraries from your profile page by
clicking on your user name at the top right of any screen.